Aegis Sciences Corporation

aegislabs.com · American English

Comprehensive drug testing solutions offer an objective measure of a patient’s drug use. Definitive testing provides information that saves lives.

rss2 wordpress content atom dc sy

Open the feed

https://www.aegislabs.com/feed/

Last post: Aug 7, 2026
Posts in 24 h · 7 days · 30 days: 0 · 0 · 0
Our last check: Answering
Served from: United States
Site title: Home
Text score at discovery: 10,466
Format: rss2
Features in the feed: content, atom, dc, sy
Community: wordpress

Posts

What our queue read from this feed. Open one to read it here, or go to the site that published it.

Aegis Sciences Names Joel Galanter Interim CEO
Aug 7, 2026 · original
August 7, 2026, Nashville, Tennessee – Aegis Sciences Corporation (“Aegis” or the “Company”) today announced it has named Joel Galanter Interim CEO, replacing Frank Basile who served as the company’s CEO since 2017. With more than a decade in senior executive leadership at Aegis, Galanter brings deep institutional knowledge and broad experience across the Company’s operations, regulatory environment, and strategic priorities. Galanter has directly overseen the Company’s legal, regulatory, governmental affairs, and corporate governance functions since 2013. Widely respected across the toxicology and laboratory industries, Galanter has provided national leadership in advancing policies and initiatives that expand access to diagnostic testing to equip clinicians with the critical tools necessary to address the evolving challenges of the opioid epidemic. “I am honored by the Aegis Board of D
Aegis Selected as a UnitedHealthcare Preferred Lab Network Provider for the Fifth Year in a Row
Jul 7, 2026 · original
NASHVILLE, Tenn., July 1, 2026 – Aegis is pleased to announce that, following a rigorous review process, it has been selected for the fifth consecutive year to participate as a UnitedHealthcare Preferred Lab Network (PLN) provider for the term 7/1/26 – 6/30/27. The Preferred Lab Network consists of currently contracted independent, freestanding laboratory care providers that have met higher standards for access, cost, data, quality, and service. For over 35 years, Aegis has been a national leader in healthcare and forensic laboratory sciences. Aegis provides clear, reliable, and actionable information on individuals’ prescription and non-prescription substance use to help healthcare providers deliver the best care. Aegis offers a flexible and customizable testing menu of over 320 drugs/metabolites which include 100+ novel psychoactive substances, to stay current with the rapidly changing
Making Sense of Benzodiazepine Results: Clinical and Practical Implications of POCT vs. Definitive Testing
Apr 20, 2026 · original
Highlights & Clinical Takeaways Negative benzodiazepine POCT results do not reliably exclude exposure. Immunoassay screens frequently miss commonly prescribed benzodiazepines (e.g., lorazepam, clonazepam, alprazolam metabolites) and designer benzodiazepines. Designer benzodiazepines are often invisible to POCT. In a DBZD‑positive cohort, approximately two‑thirds of samples with confirmed exposure were negative on point‑of‑care immunoassay testing, creating false reassurance. Reliance on POCT‑driven reflex testing can miss most nonprescribed benzodiazepine use. If definitive testing is ordered only when POCT results are “unexpected,” the majority of DBZD exposures may go undetected. Discordant results have real clinical consequences. False‑negative POCT findings can affect adherence assessments, underestimate polysubstance risk (especially with opioids), and delay recognition of benzodiaz
Aegis Sciences Corporation Announces Updates for NPS Testing
Dec 16, 2025 · original
NASHVILLE, TN. (December 15, 2025) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce the second bi-annual update to its novel psychoactive substance (NPS) testing menu. Aegis regularly reviews and updates its NPS testing menu to maintain clinical relevance and align with recommendations from the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologists (SOFT) NPS Committee. The latest update incorporates CFSRE’s tier one and tier two scope recommendations for Q2 2025. CFSRE recently added two new categories to its scope recommendations: “Semi-synthetic Cannabinoids” and “Miscellaneous.” Semi-synthetic cannabinoids will now be included in Aegis’s traditional cannabinoid test, while synthetic cannabinoids will remain a separate orderable test code. Additionally, the NPS testing menu now includes
NPS Frontline Alert: Emerging Substances
Nov 10, 2025 · original
NASHVILLE, TN. (November 10, 2025) – To stay current with the rapidly changing landscape of new and emerging drugs, Aegis has committed to bi-annual NPS test menu updates to include the tier one and tier two recommendations established collaboratively by the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. We have identified 9 new substances not previously detected in our laboratory. Details on Findings for Substances Added to NPS Testing in November 2025 (Total samples tested with positive findings: 1,163) Findings reflect reported results from samples received for testing between 6/2/2025-11/4/2025 and reported as of 11/6/2025. Samples may be positive for more than one substance. Emerging Threat Spotlight: Phenazolam Use Continues to Rise About Phenazolam Phenazolam, also known as clobromazolam, was first reported
What Did My Patient Actually Take? An Overview of Kratom Alkaloids in Clinical Practice
Nov 10, 2025 · original
Highlights & Clinical Takeaways Kratom (mitragynine) use has increased in the U.S., with products now including more potent compounds (e.g., 7‑hydroxymitragynine, mitragynine pseudoindoxyl). Product labeling may not reflect actual contents, and patients may unknowingly consume more potent compounds due to variability and mislabeling. 7‑hydroxymitragynine and mitragynine pseudoindoxyl have greater µ‑opioid receptor affinity and potency than mitragynine, contributing to analgesia and, at higher exposures, respiratory depression. Kratom effects vary by dose and formulation, with lower doses producing stimulant-like effects and higher doses producing opioid-like effects. Standard drug screens typically do not detect kratom or its key alkaloids; definitive testing is indicated when use is suspected to support accurate interpretation and clinical decision-making. Background Kratom is a psychoa
Stop Lab Cuts
Nov 5, 2025 · original
Medicare payment cuts threaten patient access to clinical laboratory services, which are essential to preventing and diagnosing diseases and conditions, empowering patients and their clinicians to make informed decisions about care. Tell Congress to pass the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act this year. Screening and diagnostic tests performed by clinical laboratories inform life’s most important health care decisions. Scheduled reimbursement cuts under the Protecting Access to Medicare Act (PAMA) could jeopardize access to many of the clinical laboratory tests that are used to screen, diagnose, monitor, and manage common diseases for all patients, including more than 60 million seniors. But the threat doesn’t stop there. After three rounds of up to 10 percent cuts, planned payment reductions of up to an additional 15 percent in 2026
Opioid Use Disorder: Evaluating Risk of Return to Use
Oct 16, 2025 · original
Highlights & Clinical Takeaways OUD is a chronic condition with high risk of return to use. Without treatment, recurrence can reach 80–90%; even with medication-assisted treatment, risk persists and long-term remission is challenging. The opioid crisis is becoming more complex. The current “fourth wave” is driven by fentanyl and polysubstance use (e.g., stimulants, benzodiazepines), increasing overdose risk and complicating care. Return to use should be expected and proactively managed. Like other chronic diseases, recurrence is common—requiring ongoing monitoring, harm reduction, and continued access to treatment. Early detection is critical for patient safety. Identifying return to use quickly enables timely intervention, reduces overdose risk, and supports appropriate care adjustments. Definitive testing strengthens clinical decision-making. It provides more accurate and comprehensive
NPS Frontline Alert: Emerging Substances
Aug 13, 2025 · original
NASHVILLE, TN. (August 13, 2025) – To stay current with the rapidly changing landscape of new and emerging drugs, Aegis has committed to bi-annual NPS test menu updates to include the tier one and tier two recommendations established collaboratively by the Center for Forensic Science Research and Education (CFSRE) and the Society of Forensic Toxicologist (SOFT) NPS Committee. Since implementation of our previous test update in June 2025, we have identified 6 new substances not previously detected in our laboratory. Details on Findings for Substances Added to NPS Testing in June 2025 (Total samples tested with positive findings: 447) Findings reflect reported results from samples received for testing between 6/2/2025-8/1/2025 and reported as of 8/4/2025. Samples may be positive for more than one substance. Emerging Threat Spotlight: Rising Detection of Phenazolam and Desalkylgidazepam Abo

Discovered by the rss-feed-index crawler, which checks each feed at most once a month.

Same record as JSON: https://api.agentalog.com/api/feeds/fd_aegislabs_com_1b45c01dd83a2c19. More from this site: aegislabs.com in the Feeds tab.